Cargando…

The Therapeutic Effectiveness of the Coadministration of Weekly Risedronate and Proton Pump Inhibitor in Osteoporosis Treatment

This trial was conducted to investigate the long-term effects of proton pump inhibitor (PPI) coadministration on the efficacy of weekly risedronate treatment for osteoporosis. Ninety-six women over 50 years old with low bone mineral density (BMD) participated in this trial. Subjects were randomly di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Mizue, Itoh, Soichiro, Yoshioka, Taro, Yamashita, Kimihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4241743/ https://www.ncbi.nlm.nih.gov/pubmed/25436170 http://dx.doi.org/10.1155/2014/607145

Ejemplares similares

Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation
por: Tanaka, Mizue, et al.
Publicado: (2018)

Anti-fracture Efficacy of Monthly Risedronate Compared with That of Weekly Risedronate in Postmenopausal Korean Women with Osteoporosis: A Nationwide Cohort Study
por: Cho, Yong Ho, et al.
Publicado: (2020)

Once-monthly risedronate for postmenopausal osteoporosis
por: Casadei, Kristina, et al.
Publicado: (2010)

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
por: McClung, M. R., et al.
Publicado: (2012)

Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors
por: Sharma, Shringi, et al.
Publicado: (2022)

Review of the safety and efficacy of risedronate for the treatment of male osteoporosis
por: Bobba, Raja, et al.
Publicado: (2007)

The cause of failure to return to the pre-fracture place of residence and solution to continue medical treatment for osteoporosis following an operation for hip fracture – Periodic observation of single center
por: Tanaka, Mizue, et al.
Publicado: (2016)

Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients
por: Minakuchi, Hitoshi, et al.
Publicado: (2020)

Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole
por: Mafuru, Magesa, et al.
Publicado: (2021)

Comparison of effectiveness and safety of ibandronate and minodronate combined with eldecalcitol in primary osteoporosis of women: A 1-year follow-up study
por: Tanaka, Mizue, et al.
Publicado: (2017)

Proton Pump Inhibitors and Osteoporosis: Is Collagen a Direct Target?
por: Ghebre, Yohannes T.
Publicado: (2020)

Cost–effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
por: Casado, Enrique, et al.
Publicado: (2023)

Use of proton pump inhibitors in general practice
por: Tosetti, Cesare, et al.
Publicado: (2017)

Risedronate’s Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis
por: Gates, Brian J., et al.
Publicado: (2012)

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
por: Masud, Tahir, et al.
Publicado: (2009)

Proton pump inhibitors increase risk of COVID-19
Publicado: (2020)

Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA
por: Eisman, John A., et al.
Publicado: (2023)

Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma
por: Dell’Anno, Irene, et al.
Publicado: (2020)

Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
por: Moro-Álvarez, María J, et al.
Publicado: (2008)

Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation
por: Kinov, Plamen, et al.
Publicado: (2012)

Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials
por: Shigematsu, Takashi, et al.
Publicado: (2017)

A clinical therapeutic protein drug–drug interaction study: coadministration of denosumab and midazolam in postmenopausal women with osteoporosis
por: Jang, Graham, et al.
Publicado: (2014)

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
por: Rackoff, Paula
Publicado: (2009)

Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran
por: Ebadi Fard Azar, Amir Ali, et al.
Publicado: (2017)

Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France
por: Hiligsmann, M., et al.
Publicado: (2019)

Proton pump inhibitors increase the severity of hepatic encephalopathy in cirrhotic patients
por: Fasullo, Matthew, et al.
Publicado: (2019)

Influence of proton pump inhibitors in the development of spontaneous bacterial peritonitis
por: Miozzo, Suelen A S, et al.
Publicado: (2017)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy
por: Sakurai, Kouichi, et al.
Publicado: (2017)

Proton pump inhibitor induced collagen expression in colonocytes is associated with collagenous colitis
por: Mori, Shiori, et al.
Publicado: (2017)

A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data
por: McClung, Michael R., et al.
Publicado: (2012)

Effects of teriparatide compared with risedronate in the treatment of osteoporosis: A meta-analysis of randomized controlled trials
por: Yang, Chengzhi, et al.
Publicado: (2020)

Enhancing Osteoporosis Treatment through Targeted Nanoparticle Delivery of Risedronate: In Vivo Evaluation and Bioavailability Enhancement
por: Saifi, Zoya, et al.
Publicado: (2023)

Is There Any Association of Osteoporosis With Proton Pump Inhibitor Use? (Gastroenterology 2010;138:896-904)
por: Jung, Hye-Kyung
Publicado: (2010)

Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy
por: Kawara, Fumiaki, et al.
Publicado: (2017)

Washed microbiota transplantation reduces proton pump inhibitor dependency in nonerosive reflux disease
por: Zheng, Ya-Mei, et al.
Publicado: (2021)

Effects of Risedronate on Osteoarthritis of the Knee
por: Iwamoto, Jun, et al.
Publicado: (2010)

A 3-year postmarketing study on the safety and effectiveness of once-monthly risedronate in Japanese patients with osteoporosis
por: Soen, Satoshi, et al.
Publicado: (2020)

Zoledronic acid is effective in the management of migratory osteoporosis unresponsive to conservative treatment and risedronate: A case report
por: Evangelatos, Gerasimos, et al.
Publicado: (2021)

Proton Pump Inhibitors and Gastritis
por: Suzuki, Masayuki, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_l955l9lv2epkkreo5upkqkmd3s